Immune-Focused Discovery Firm Alpine Goes Public With Nivalis Merger
Mitchell Gold, who once led Dendreon, will lead the company, which obtains $90m in funding to bring forward three potential drug candidates for inflammatory conditions and cancer.
Mitchell Gold, who once led Dendreon, will lead the company, which obtains $90m in funding to bring forward three potential drug candidates for inflammatory conditions and cancer.